The Motley Fool Discussion Boards

Previous Page

Industry Discussions / Biotechnology


Subject:  Re: The CRSPR catch... Date:  10/25/2020  7:54 AM
Author:  2K10 Number:  25449 of 25623

I'm hopeful for SGMO zinc fingers tech for genetic therapies.

As you have noted, BLUE lentiglobin tech is doing well. Last I checked in with them they were doing well on hemophilia and thalassemia trials.

CRISPR seems like it has reputation / too high a risk of off-target modifications.

Allogenic off the shelf therapy is a dream and worth pursuing but seems very far off based on these results.

No position in any of these right now.
Copyright 1996-2021 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us